Arcutis Biotherapeutics, Inc. (ARQT) vs Dianthus Therapeutics, Inc. (DNTH)
- Arcutis Biotherapeutics, Inc. ARQT 28.82 −0.96%
- Dianthus Therapeutics, Inc. DNTH 72.09 −3.27%
Arcutis Biotherapeutics, Inc. and Dianthus Therapeutics, Inc. are both Biotechnology companies. Dianthus Therapeutics, Inc. is the larger, with a market value of $4.2B against $3.7B — 1.1× the size. Dianthus Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 131×. Arcutis Biotherapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against −60.8%. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs −10,097.0%) and the higher return on invested capital (23.6% vs −47.7%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 12 and Dianthus Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | ARQT | DNTH | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.14% | 100.00% | 65.16% |
| Operating margin | 7.38% | (11,441.39%) | 0.00% |
| Net margin | 6.15% | (10,096.95%) | 0.00% |
| Free cash flow margin | 8.42% | (8,177.99%) | 0.00% |
| Return on equity | 15.86% | (26.07%) | (56.36%) |
| Return on assets | 6.78% | (24.98%) | (48.04%) |
| Return on invested capital | 23.62% | (47.74%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack